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A system has been designed to study the in vivo forward rate of mutation of human immunodeficiency virus type 1 (HIV-
1) during one round of replication. A HIV-1 shuttle vector was used that contained the lacZa peptide gene as a reporter
for mutations. The forward mutation rate of HIV-1 was found to be 3 1 1005 mutations per target base pair per cycle, or
about 20-fold lower than the error rates reported for purified HIV-1 reverse transcriptase with sense-strand RNA and DNA
templates of the lacZa peptide gene in a cell-free system. To test the hypothesis that the vpr gene product might, at least
in part, account for the lower mutation rate observed in vivo, a HIV-1 vector was replicated to determine if the mutation
rate was higher in the absence of the wild-type vpr gene product. A vpr0 shuttle vector had an overall mutation rate as
much as 4-fold higher than that of the parental vector. A shuttle vector with an amino acid substitution in Vpr that prevents
efficient incorporation of Vpr into virus particles was found to have a mutation frequency similar to that of the vpr0 vector,
and was interpreted to indicate a requirement for Vpr incorporation into the virus particle in order to observe the influence
of vpr on the mutation rate. Replication of a vpr0 shuttle vector in the presence of a wild-type vpr expression plasmid led
to a mutation frequency similar to that of the parental vector, suggesting that the vpr mutation could be complemented in
trans. Immunoprecipitation analysis indicated that Vpr virion incorporation coincided with the influence of vpr on the mutation
rate. q 1996 Academic Press, Inc.
INTRODUCTION the average lifetime of an HIV-1-infected cell is less than
1 to 2 days (Ho et al., 1995; Wei et al., 1995).
The Retroviridae family of RNA viruses replicate
A system has been developed to measure the forward
through a DNA intermediate (Baltimore, 1970; Temin and
mutation rate of HIV-1 with a vector containing the lacZa
Mitzutani, 1970). The viral RNA is copied into DNA by the peptide gene as a reporter for mutations (Mansky and
viral-encoded enzyme reverse transcriptase in a process Temin, 1995). This system allows for the study of muta-
known as reverse transcription. The process of reverse tions that occur during a single round of HIV-1 replication.
transcription is known to be error-prone, contributing to The mutation rate of HIV-1 in this system was determined
the high genetic variability of retroviruses (Coffin, 1992; to be 3 1 1005 mutations per target base pair per cycle
Holland et al., 1992; Katz and Skalka, 1990; Temin, 1961). in HeLa cells (Mansky and Temin, 1995) and 4 1 1005
The error-prone nature of reverse transcription has been mutations per target base pair per cycle in a T-lymphoid
proposed to be due to abnormal strand transfers that cell line (Mansky, 1996). The most commonly detected
can occur during this process (Temin, 1993). The level mutations were base substitution mutations (G to A and
of genetic variation of human immunodeficiency virus C to T transition mutations) and frameshift mutations (01
type 1 (HIV-1) is high (Alizon et al., 1986; Balfe et al., frameshifts in runs of Ts and As). This mutation rate is
1990; Cheng-Mayer et al., 1991; Hahn et al., 1986; Levy, maximally 5% of the reported error rates for purified HIV-
1993; Starcich et al., 1986; Wong-Staal, 1990) relative to 1 reverse transcriptase with a sense-strand RNA and
some retroviruses in other genera (Dube et al., 1993; DNA template in cell-free studies, indicating that the mu-
Ratner et al., 1991; Willems et al., 1993). Genetic variation tation rate of HIV-1 is less than that predicted by the
of retroviruses can be viewed as the composite of several measured fidelity of purified HIV-1 reverse transcriptase
variables: (1) the mutation rate per replication cycle, (2) (Boyer et al., 1992).
the number of replication cycles, (3) the fixation rate of The difference between the in vivo mutation rate of
mutations, and (4) the rate of recombination (Coffin, 1990; HIV-1 and the error rate of purified HIV-1 reverse tran-
Hu and Temin, 1990; Zhang and Temin, 1993). It has scriptase may be due to several possibilities. One hy-
been argued that HIV-1 completes about 300 or more pothesis is that, in vivo, protein factors and reverse tran-
cycles per year (Coffin, 1995), based on the reports that scriptase together contribute to the accuracy of reverse
transcription; in the absence of these factors, the error
rate of purified reverse transcriptase is higher. Protein1 This paper is dedicated to the memory of Howard M. Temin.
2 Fax: (608) 262-2824; E-mail: mansky@oncology.wisc.edu. factors that are viral proteins would be predicted, like
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FIG. 1. HIV-1 shuttle vector used for mutation rate studies. The HIV-1 shuttle vector is shown in the proviral DNA form. Solid black boxes represent
the HIV-1 long terminal repeats (LTRs). Solid black lines indicate viral sequences. Rectangular boxes above the solid black lines indicate viral
coding sequences, with the relative locations of the boxes corresponding to the translational reading frame. Retroviral genes are indicated as vif,
vpr, tat, rev, vpu, and nef. Bent lines in between the coding regions for tat and rev show reading frames joined by splicing events. E indicates the
location of the encapsidation signal. The simian virus 40 promoter (SV) is represented as a cross-hatched box, the neo gene is represented as a
hatched rectangular box, the pACYC origin of replication is represented as the light gray box, and the lacZa peptide gene is represented as an
open rectangular box with a black band representing the lac operator sequence. Dashed lines indicate deleted viral coding sequence removed by
digestion with SwaI. The StuI and XhoI sites were used in the purification of the vector proviral DNA containing the neo gene, the pACYC origin of
replication, and the lacZa peptide gene.
reverse transcriptase, to be present in virus particles. To made by a primary/combinatorial two-step polymerase
test the hypothesis that viral proteins contribute to the chain reaction (PCR) protocol (Ito et al., 1991). Oligonu-
accuracy of reverse transcription, the HIV-1 vpr gene was cleotide primers that changed the start codon of the vpr
mutated in order to determine the influence of vpr on the gene from ATG to ATT, but did not affect the overlapping
rate of mutation. The vpr gene encodes a 96-amino-acid, vif open reading frame, were used as internal primers.
nonstructural protein that is associated with virus parti- The PCR product from this reaction, containing the vpr
cles (Cohen et al., 1990) and that requires the p6 region gene with the mutation of the start codon, was cloned
of the gag gene for incorporation (Kondo et al., 1995; Lu into the pCRII cloning vector (Invitrogen Corp., San Diego,
et al., 1995, 1993; Paxton et al., 1993). The incorporation CA). The cloned DNA was sequenced to verify the intro-
of Vpr into virus particles implies a role either early in duced mutations using a nonradioactive DNA sequenc-
the HIV-1 replication cycle (prior to the synthesis of new ing kit (Silver Sequencing kit; Promega Corp., Madison,
viral proteins) or late in the replication cycle (during as- WI) and digested with PflMI and SalI, and the fragment
sembly and budding). Specific roles of vpr include the containing the vpr gene was cloned into the PflMI and
nuclear localization of the preintegration complex and SalI sites of pHIV shuttle 3.12.
prevention of cell proliferation during chronic infection The construction of the Vpr virion-incorporation mutant
(He et al., 1995; Heinzinger et al., 1994; Jowett et al., was made using a similar PCR mutagenesis protocol
1995; Planelles et al., 1995; Rogel et al., 1995). This study used for pHIV shuttle 3.12 vprATG0 (as described above).
has found that the mutation rate of a vpr0 vector mutant Nucleotide changes in the vpr gene of HIV shuttle 3.12
was as much as fourfold higher than that of the vpr/ were made that led to changes in the coding for amino
parental vector. This observation supports an early role acid 30 (alanine to phenylalanine; Vpr mutant A30F); this
of vpr in the HIV-1 replication cycle. These data support residue is near the amino-terminal end of Vpr in the
the conclusion that the vpr gene partially accounts for predicted a-helical region of the protein (residues 17–
the lower than predicted in vivo mutation rate of HIV-1. 34). Mutagenesis of this domain has been found to affect
Vpr stability and the efficiency of Vpr incorporation into
MATERIALS AND METHODS virions (Mahalingam et al., 1995a,b,c). This particular
amino acid substitution mutation in the vpr gene has
HIV-1 vectors and expression plasmids
been previously reported to limit the incorporation of Vpr
into virus particles (Yao et al., 1995).The plasmid pHIV shuttle 3.12 (Fig. 1) was constructed
The HIV-1 gag–pol expression plasmid used, pSVgag-as described (Mansky and Temin, 1995). A vpr0 derivative
of pHIV shuttle 3.12, pHIV shuttle 3.12 vpr ATG0, was pol-rre-r (Smith et al., 1990), was kindly provided by David
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Rekosh, University of Virginia. The amphotropic murine mids and the HIV-1 tat expression plasmid (Step 2 cells);
in complementation experiments, pCMVvpr was tran-leukemia virus env expression plasmid used, pSV-A-
MLV-env (Landau and Littman, 1992), was provided by siently transfected along with these plasmids. Step 2
clones were tested by Southern analysis to ensure thatDan Littman, University of California, San Francisco. The
vpr expression plasmid, pCMVvpr, was constructed by only a single vector proviral DNA was present. The lacZa
peptide gene in the vector proviral DNA of Step 2 clonesamplifying the vpr gene from HIV shuttle 3.12 by PCR
and inserting it into a eukaryotic expression vector that was sequenced to confirm that no mutations were intro-
duced. In Step 3, vector virus was transferred to freshcontains the CMV promotor (pCR3; Invitrogen).
HeLa target cells by cocultivation 24–48 hr after transient
Cells and media transfection of helper plasmids; cells were then placed
under G418 selection (Step 3 cells). Cocultivation wasThe HeLa and COS-1 cell lines used were obtained
used to produce Step 3 cells to maximize the number offrom the American Type Culture Collection (Rockville,
Step 3 cells for analysis of the mutation rate.MD) and were maintained in Temin’s modified Eagle’s
medium (Temin, 1968) containing 10% calf serum or 10%
Recovery of shuttle vector proviral DNA and DNAfetal bovine serum, respectively.
sequencing of the lacZa peptide region
Transfections, infections, and cocultivations Purified genomic DNA (Sambrook et al., 1989) from
pools of Step 3 clones was digested with the restrictionHIV-1 vectors and expression plasmids were trans-
enzymes StuI and XhoI, to release the neo, pACYC originfected into COS-1 or HeLa cells by use of DMSO/poly-
of replication, and lacZa peptide gene sequences frombrene (Kawai and Nishizawa, 1984). HeLa cells were
the HIV-1 shuttle vector proviral DNA (Fig. 1). Proviralinfected in the presence of polybrene (Mansky, 1994).
DNA was purified with the Lac repressor protein (Pro-Infection of HeLa target cells was done by cocultivation
mega) as previously described (Mansky and Temin,of virus-producing cells with target cells (Mansky et al.,
1994). The purified proviral DNA was treated with the1995; Mansky and Temin, 1994). Briefly, virus-producing
Klenow fragment of DNA polymerase to fill in single-cells (typically 2.5 1 105 cells per 60-mm petri dish, 5 1
stranded ends, and was ligated and used to electropor-105 cells per 100-mm petri dish, or 7.5 1 105 cells per
ate competent Escherichia coli XLI Blue cells. Kanamy-150-mm petri dish) were treated with mitomycin C (10
cin-resistant bacterial colonies were selected in themg/ml), an inhibitor of host cell DNA synthesis, for 2 hr
presence of the 5-bromo-4-chloro-3-indolyl-b-D-thioga-at 377. The cells were then washed three times with fresh
lactopyranoside inducer. The ratio of white plus light-bluemedium, and HeLa target cells equivalent to the number
bacterial colonies to total bacterial colonies observedof treated virus-producing cells were added. Two days
provided a forward mutation rate for a single retroviralafter cocultivation, selective medium containing G418
replication cycle. Plasmid DNA was purified (Sambrookwas added. Control experiments were done with each
et al., 1989) and sequenced in the lacZa peptide genecocultivation experiment to ensure that mitomycin C-
region with a nonradioactive DNA sequencing kit (Pro-treated, virus-producing cells did not proliferate and no
mega Corp.) and by an automated DNA sequencer (Ap-longer adhered to the surfaces of culture dishes. Cells
plied Biosystems).expressing the neo gene were selected with the neomy-
cin phosphotransferase analog, G418, until the formation
Cell radiolabeling and immunoprecipitation analysisof colonies (typically about 3 weeks).
Step 2 cells with HIV shuttle 3.12 or derivatives with
Strategy for generating a single cycle of retrovirus
vpr mutations were metabolically labeled with [35S]-
replication
methionine (100 mCi/ml) for approximately 15 hr after
transfection with helper plasmids. Virus particles pro-The experimental protocol developed to assay a single
cycle of HIV-1 shuttle vector replication is shown in Fig. duced during the labeling were pelleted through a 20%
sucrose cushion in a Beckman SW28 rotor for 90 min2. The protocol contains three steps. In Step 1, the HIV-
1 shuttle vector was introduced into COS-1 cells by trans- at 47. Cells and pelleted virions were lysed in immuno-
precipitation buffer (1% Triton X-100, 0.5% deoxycho-fection and placed under G418 selection. Cell clones
were then transiently transfected with the helper plas- late, 0.1% sodium dodecyl sulfate, and 0.2 mM phenyl-
methylsulfonyl fluoride in phosphate-buffered saline)mids pSVgagpol-rre-r and pSV-A-MLV-env along with a
HIV-1 tat expression plasmid, pSVtat (Kao et al., 1987; and then immunoprecipitated with a rabbit anti-Vpr se-
rum (deposited by L. Ratner in the AIDS Research andPeterlin et al., 1986) (to aid in expression of the accessory
genes from the shuttle vector). In Step 2, vector virus Reference Reagent Program, National Institute of Al-
lergy and Infectious Diseases, Bethesda, MD) ab-was harvested 48 hr posttransfection from Step 1 cells
and used to infect fresh HeLa cells. G418-resistant cell sorbed to protein A – agarose beads (Bethesda Re-
search Laboratories, Gaithersburg, MD).clones were transiently transfected with the helper plas-
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FIG. 2. Experimental protocol for studying one round of HIV-1 shuttle vector virus replication. (A) Experimental protocol. In Step 1, COS-1 cells
were transfected with a pHIV shuttle 3.12 or a derivative and were placed under G418 selection. These cells were transiently transfected with the
HIV-1 gag–pol expression plasmid, pSVGAGPOL-rre-r, the amphotropic murine leukemia virus env gene, pSV-A-MLV-env, and a HIV-1 tat expression
plasmid, pSVtat (to aid in expression of the accessory genes from the shuttle vector). Fourty-eight hours posttransfection, virus was harvested and
used to infect HeLa cells. G418-resistant cell clones were transiently transfected with pSVGAGPOL-rre-r, pSV-A-MLV-env, and the tat expression
plasmid (Step 2 cells). Twenty-four to 48 hr posttransfection, Step 2 cells were treated with mitomycin C and cocultivated with fresh HeLa target
cells, and all cells were placed under G418 selection (Step 3 cells). (B) One round of HIV-1 shuttle vector virus replication. The steps going from
a parental shuttle vector provirus in the Step 2 cell to a vector provirus in the Step 3 cell constitute a single cycle of replication. These steps include
transcription of the proviral DNA by the cellular transcription machinery, packaging of the viral RNA, release of viral particles, infection of target
cells, reverse transcription, and integration of newly synthesized viral DNA to generate a vector provirus.
RESULTS or 7.5 1 105 cells per 150-mm petri dish; mitomycin C
is an inhibitor of host cell DNA synthesis and led to
Replication of the HIV-1 shuttle vectors containing cell death of Step 2 cells as described under Materials
mutations of the vpr gene and Methods) with fresh HeLa target cells to produce
Step 3 cells led to titers of 8 1 102 – 3 1 103 CFU/2.5 1The HIV-1 shuttle vectors used in these studies were
105 HeLa target cells. The steps going from a parentalbased on HIV shuttle vector 3.12 (Fig. 1), which contains
shuttle vector provirus in the Step 2 cells to a vectora deletion in the gag–pol and env genes with an inser-
provirus in the Step 3 cells constitute a single cycletion, in the env gene, of a cassette containing the neo
of replication (Fig. 2). These steps include transcrip-gene, the pACYC origin of replication, and the lacZa
tion of the proviral DNA by the cellular transcriptionpeptide gene. These vectors replicate in mammalian
machinery, packaging of the viral RNA, release of viralcells as a virus and can be selected with the neomycin
particles, infection of target cells, reverse transcrip-analog G418. The vectors can replicate in E. coli as a
tion, and integration of newly synthesized viral DNAplasmid and are selected using the drug kanamycin. To
to generate a vector provirus. Southern analysis ofbe packaged into a virus particle, these vectors are com-
total DNA from each Step 2 cell clone (after transientplemented in trans by transient transfection of cells with
transfection with the helper plasmids) of HIV shuttlean HIV-1 gag–pol expression plasmid and an ampho-
3.12 or derivatives was done to ensure that each celltropic murine leukemia virus env expression plasmid.
clone used contained only one provirus copy (data notVector virus produced from either COS-1 or HeLa
shown). Proviral DNA from at least 5 1 105 cells ofcells was used to infect fresh HeLa target cells (Fig.
each Step 2 cell clone was purified using the Lac2). Cocultivation was used to produce Step 3 cells
repressor protein and introduced into E. coli to screenbecause it was desirable to obtain the largest number
for mutations in the lacZa gene region; blue coloniesof Step 3 cells for analysis of the mutation rate. Cocul-
were observed for each Step 2 clone (data not shown),tivation of mitomycin C-treated Step 2 cells of HIV
indicating that the bacterial colonies containing vectorshuttle 3.12 or derivatives (typically 2.5 1 105 cells per
60-mm petri dish, 5 1 105 cells per 100-mm petri dish, proviral DNA had the wild-type lacZa gene phenotype.
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TABLE 1 screened for vpr0 shuttle vector proviral DNAs containing
mutations in the lacZa peptide gene (Table 1). Fifty ofMutation Frequency in Recovered Proviruses for a vpr0
these colonies had a white or light-blue colony colorHIV Shuttle Vector 3.12 Mutant
phenotype. The mutation frequency was 50/3254 or 15
No. of mutants/ 1 1003 mutations per cycle. This mutation frequency was
Step 2 total No. of Mutation about four times that of the mutation frequency of the
Mutant clone No. bacterial colonies frequency
vpr/ parental vector (24/6462 or 4 1 1003 mutations per
cycle) in parallel experiments (Table 1). The mutationHIV shuttle 3.12
vpr ATG0 1 10/795 13 1 1003 frequencies of the vpr0 mutant and the parental shuttle
2 17/1025 17 1 1003 vector were significantly different (x2  38; P  0.01).
3 12/881 14 1 1003 To determine the types of mutations in the lacZa pep-
4 11/553 20 1 1003
tide gene and to calculate the mutations per base pairTotal 50/3254 15 1 1003 a
per cycle, plasmid DNA from these clones was analyzedParental, vpr/
HIV shuttle by DNA sequencing in this region. Forty-two of the 50
vector 3.12 1 8/1383 6 1 1003 mutants sequenced from the vpr0 shuttle vector were
2 13/3724 4 1 1003 found to contain a single mutation in the lacZa peptide
3 3/1355 2 1 1003
gene region (Fig. 3). Similar kinds of mutations wereTotal 24/6462 4 1 1003 b
observed with the vpr/ parental vector (Fig. 3).
a Average mutation frequency with a standard deviation of 3 1 1003 Eight of the 50 mutants sequenced from the vpr0 shut-
mutants per cycle. tle vector had multiple mutations in the lacZa peptide
b Average mutation frequency with a standard deviation of 2 1 1003 gene region. Most of the mutants contained multiple G
mutants per cycle.
to A transition mutations. These mutants are likely to
have resulted from proviral DNA synthesis catalyzed by
an error-prone reverse transcriptase. Since the forwardThe lacZa gene region in the vector proviral DNA of
mutation rate of HIV-1 is 3 1 1005 mutations per baseeach Step 2 clone was sequenced to confirm that no
pair per cycle (Mansky and Temin, 1995), the observationmutations had been introduced into the lacZa gene
of 2 or more mutations in the 280-base lacZa peptideregion in the steps leading to the vector provirus in
gene region is indicative of hypermutation (Pathak andthe Step 2 cell. The templates used for DNA sequenc-
Temin, 1990a).ing were from proviral DNA purified from Step 2 cells
using the Lac repressor protein and proviral DNAs
from at least three blue colonies (from the above phe- Effect of a mutation that limits incorporation of Vpr
into virus particles on the mutation ratenotypic analysis in E. coli) for each Step 2 clone used;
DNA sequencing indicated that each Step 2 clone con-
A mutation in the vpr gene was made that wouldtained the wild-type lacZa gene sequence (data not
limit incorporation of Vpr into virus particles, withoutshown). The vpr gene in the vector proviral DNA of the
resulting in large structural changes to the protein. Spe-parental Step 2 clones was sequenced to confirm that
cifically, a vpr mutant based on HIV shuttle 3.12 wasno mutations had been introduced in the steps leading
made that would express Vpr with a single amino acidto the vector provirus in the Step 2 cell (data not
substitution at residue 30 (changing alanine to phenyl-shown).
alanine) in the a-helical domain located near the amino
terminus of the protein; this mutant has been reportedMutation frequency, type, and location observed with
to limit the incorporation of Vpr into virus particles (Yaoa vpr0HIV-1 shuttle vector
et al., 1995). Vector virus produced from COS-1 cells
was used to infect fresh HeLa target cells. Step 2 cellsA HIV-1 shuttle vector containing a mutation of the vpr
gene start codon was used (i.e., HIV shuttle 3.12 vpr containing this shuttle vector were transfected with the
helper plasmids, and were cocultivated with fresh HeLaATG0). This vector was tested in parallel with the parental
vector (Table 1). The proviral DNA from pooled Step 3 target cells to produce Step 3 cells in parallel with
cocultivation of fresh HeLa cells with the vpr/ parentalcells representing over 70,000 different cell clones of the
vpr0 mutant was purified with the Lac repressor protein shuttle vector.
The proviral DNA from pooled Step 3 cells represent-and introduced into E. coli to screen for mutations in the
lacZa gene region. Vector DNAs with mutations at target ing over 50,000 different cell clones was purified with
the Lac repressor protein and introduced into E. coli tonucleotides, previously determined to lead to a pheno-
typic change (Bebenek et al., 1989; Pathak and Temin, screen for mutations in the lacZa gene region. Three
thousand ninety-two bacterial colonies were screened1990b), were detectable as bacterial colonies with a
white or light-blue colony color phenotype. Three thou- for shuttle vector proviral DNAs containing mutations in
the lacZa peptide gene (Table 2). Fourty-four of thesesand two hundred fifty-four bacterial colonies were
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FIG. 3. Plus-strand nucleotide sequence of the lacZa gene region in a HIV shuttle 3.12 derivative containing a mutation of the vpr gene start
codon. The start for nucleotide numbering is the beginning of the 5* long terminal repeat of HIV shuttle 3.12. The start and stop codons of the
lacZa open reading frame (small boxed sequences) and the lac operator sequence (large boxed sequence) are shown. Nucleotide positions of
base pair substitutions (letters above the sequence), /1 frameshifts (letters with . above the sequence), 01 frameshifts (, above the sequence),
and deletions (solid black lines with arrows above or below the sequence and adjacent to the deletion names) are indicated. Mutations from the
same mutant are designated with a Greek letter adjacent to each mutation; identical Greek letters indicate mutations from the same mutant. The
locations of base-substitution, frameshift, and deletion mutations in the parental vector, HIV shuttle vector 3.12, from parallel experiments (see Table
1) are indicated below the nucleotide sequence.
colonies had a white or light-blue colony color pheno- These cells were then cocultivated with fresh HeLa target
cells to produce Step 3 cells along with parallel cocultiva-type. The mutation frequency was 44/3092 or 14 1 1003
tion experiments using the vpr/ parental vector.mutations per cycle. The mutation frequency of the vpr/
The proviral DNA from pooled Step 3 cells representingparental vector in parallel experiments was 10/2450 or
over 50,000 different cell clones was purified with the Lac4 1 1003 mutations per cycle. The mutation frequency of
repressor protein and introduced into E. coli to screen forthe shuttle vector containing the amino acid substitution
mutations in the lacZa gene region. Two thousand ninein Vpr was significantly different from that obtained with
hundred ninety-two bacterial colonies were screened forthe parental vector (x2  14; P  0.01), but was not
vpr-complemented shuttle vector proviral DNAs containingdifferent than the mutation frequency of the vpr0 vector
mutations in the lacZa peptide gene (Table 3). Nineteen(x2  0.14; P  0.1). These results indicate the require-
of these colonies had a white or light-blue colony colorment of efficient Vpr incorporation in order to observe
phenotype. The mutation frequency for the vpr-comple-the influence of the vpr gene on the rate of mutation.
mented shuttle vector was 19/2992 or 6 1 1003 mutations
per cycle. The mutation frequency of the vpr/ parental vec-Complementation in trans of mutations in the vpr
tor done in parallel experiments was 11/2074 or 5 1 1003gene
mutations per cycle. The mutation frequency of the comple-
HIV shuttle 3.12 vpr ATG0 was used to test for comple- mented vector was not significantly different from the muta-
mentation in trans of the vpr mutations made in HIV shut- tion frequency of the parental vector (x2  0.23; P  0.1),
tle vector 3.12. Complementation was determined based but was significantly different from the mutation frequency
on the mutation rate of the vector. Step 2 cells containing of the vpr0 vector (x2  11; P  0.01). This provides evi-
HIV shuttle 3.12 vector vpr ATG0 were transfected with dence that a vpr0 vector can be complemented in trans
with a vpr expression plasmid.the helper plasmids and the vpr expression plasmid.
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TABLE 2
Mutation Frequency in Recovered Proviruses of a HIV-1 Shuttle
Vector Containing a Mutation in the vpr Gene That Limits Vpr Incorpo-
ration into Virus Particles
No. of mutants/
FIG. 4. Radioimmunoprecipitation analysis of Vpr expression andStep 2 total No. of Mutation
virion incorporation from Step 2 cells with HIV shuttle vector 3.12 orMutant clone No. bacterial colonies frequency
derivatives containing mutations in the vpr gene. Transiently
transfected Step 2 cells were metabolically labeled with [35S]Met; cell-HIV shuttle 3.12
associated and virion-associated proteins were immunoprecipitatedVpr A30F 1 9/847 11 1 1003
with a rabbit anti-Vpr serum. Lane 1, untransfected Step 2 cells with2 24/1426 17 1 1003
the parental HIV shuttle 3.12; lane 2, parental HIV shuttle 3.12; lane 3,3 11/819 13 1 1003
HIV shuttle 3.12 vpr ATG0; lane 4, HIV shuttle 3.12 Vpr A30F; lane 5,Total 44/3092 14 1 1003 a
HIV shuttle 3.12 vpr ATG0 complemented with vpr expression plasmid.Parental, vpr/
The positions of the molecular weight standards are shown on theHIV shuttle
right.vector 3.12 1 4/1387 3 1 1003
2 6/1063 6 1 1003
Total 10/2450 4 1 1003
Vpr was inefficiently expressed in nontransfected Step
a Average mutation frequency with a standard deviation of 3 1 1003 2 cells from HIV shuttle 3.12 (Fig. 4A, lane 1) relative to
mutants per cycle. Vpr in cells transiently transfected with the helper plas-
mids and the tat expression plasmid (Fig. 4A, lane 2).
The relatively low expression of Vpr from HIV shuttle 3.12
Expression of Vpr from virus-producing cells
in the untransfected Step 2 cells provides an explanation
The expression and virion-incorporation of Vpr with as to why these cells are able to proliferate in the pres-
HIV shuttle 3.12 and derivatives used in this study was ence of the wild-type vpr gene. Vpr was detected in viri-
analyzed (Fig. 4) to confirm the correlation between Vpr ons only from the transiently transfected cells producing
virion incorporation and the influence of the vpr gene on virus particles (Fig. 4B, lane 2). In total, these data sup-
the mutation rate. Expression of Vpr in cells with the vpr0 port the correlation between Vpr virion incorporation and
mutant HIV shuttle 3.12 vpr ATG0 was not detected in the influence of vpr on the mutation rate.
cells (Fig. 4A, lane 3) or virus particles (Fig. 4B, lane 3).
Vpr was expressed with HIV shuttle 3.12 Vpr A30F in DISCUSSION
cells (Fig. 4A, lanes 4), but was not detected with virus
The HIV-1 accessory gene vpr was mutated to deter-particles (Fig. 4B, lanes 4). In the trans-complementation
mine whether the vpr gene could, at least in part, accountexperiment of HIV shuttle 3.12 vpr ATG0 with a wild-type
for the lower than predicted in vivo mutation rate of HIV-vpr expression plasmid, Vpr was detected from cells (Fig.
1. Mutation of the vpr gene start codon was made and4A, lane 5) and from virus particles (Fig. 4B, lane 5).
introduced into a HIV-1 shuttle vector that has been used
to determine the in vivo mutation rate of HIV-1 (Mansky
TABLE 3 and Temin, 1995). The mutation rate of this vpr0 vector
was determined using the lacZa peptide gene as a re-Mutation Frequency in Recovered Proviruses of a vpr0 Shuttle
porter for mutations. The mutation rate of a vpr0 HIV-1Vector Complemented in trans with a vpr Expression Plasmid
was determined to be 12 1 1005 mutations per target
No. of mutants/ base pair per cycle (Table 4). This mutation rate is four-
Step 2 total No. of Mutation fold higher than that of the parental vector, 3 1 1005
Mutant clone No. bacterial colonies frequency
mutations per target base pair per cycle (Table 4). Two
additional experiments supported the influence of vpr onHIV shuttle 3.12 vpr
ATG0 plus wild- the mutation rate of HIV-1. First, a HIV-1 shuttle vector
type vpr plasmid 1 5/1041 5 1 1003 containing a mutation in the vpr gene that limits incorpo-
2 6/778 8 1 1003 ration of Vpr into virus particles had a mutation frequency
3 8/1173 7 1 1003
similar to that of the vpr0 vector. Second, the mutationTotal 19/2992 6 1 1003 a
frequency of the vpr0 vector was found to be comparableParental, vpr/ HIV
shuttle vector to the vpr/ parental vector when complemented in trans
3.12 1 4/967 4 1 1003 with a wild-type vpr expression plasmid.
2 7/1112 6 1 1003 Mutation of the vpr gene did not significantly influence
Total 11/2079 5 1 1003
the proportion of base-substitution or frameshift muta-
tions to the total number of mutants recovered, whena Average mutation frequency with a standard deviation of 1 1 1003
mutants per cycle. compared to similar proportions of the parental vector
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TABLE 4 localization of HIV-1 DNA in nondividing cells (Heinzinger
et al., 1994).Relative Rate of Mutation for a HIV-1 vpr0 Mutant and a vpr/ HIV-1
The importance of vpr in viral persistence and patho-
No. of recovered mutant shuttle genesis is unclear. Reversion of an experimentally intro-
vector proviruses duced mutation into the initiation codon of the SIV vpr
gene was associated with disease progression (Lang etMutation type HIV-1 vpr0 mutant vpr/ HIV-1
al., 1993); however, progression to AIDS can occur in the
absence of vpr (Gibbs et al., 1995). Nonsense mutationsBase-pair substitution 33 16
Frameshift 15 7 in the vpr gene have been characterized in isolates ob-
Deletion 2 1 tained from HIV-1-seropositive individuals (Nakaya et al.,
Deletion with insertion 0 0
1994), suggesting that virus persistence is associatedOverall mutation frequencya 50/3254 24/6462
with the accumulation of nonsense mutations in the vprOverall mutation rateb,c
(mutations/target bp/cycle) 12 1 1005 3 1 1005 gene.
The in vivo mutation rate of HIV-1 is 20-fold lower than
a Data from Table 1. the error rates of purified HIV-1 reverse transcriptaseb The rates of mutation were calculated as the sums of the rates of
with RNA and DNA templates of the lacZa peptide genebase-pair substitution, frameshift, and deletion mutations per 3254 total
(Boyer et al., 1992; Mansky and Temin, 1995). Mutationshuttle vector proviruses for a HIV-1 vpr0 mutant, per 6462 for vpr/
HIV-1, per 114 target nucleotides for substitutions, per 150 target nucle- of the vpr gene leads to a HIV-1 mutation rate that is
otides for frameshifts, or per 280 target nucleotides for deletion muta- fivefold lower than the in vitro error rates. This indicates
tions. Target nucleotides for substitution and frameshift (Bebenek et
that other protein factors may also influence the in vivoal., 1989; Boyer et al., 1992) and deletion mutations (Pathak and Temin,
mutation rate. The nucleocapsid protein, which is closely1990b) have been previously described.
c To calculate the overall mutation rate, multiple mutants were put associated with the genomic RNA, is part of the viral
into one of the mutation type categories based on mutations in each core particle, and is involved in the initiation of reverse
mutant that occurred at known target nucleotides in the lacZa peptide transcription (Lapadat-Tapolsky et al., 1993), could also
gene. Only one mutant in each multiple mutant was used in the calcula-
influence the accuracy of reverse transcription. Viral rep-tion of the rate.
lication accessory proteins that affect the accuracy of
replication have been described for other viruses. For
(Table 4). However, the increase in the overall mutation example, bacteriophage T4 encodes two proteins, gene
rate observed with the vpr0 vectors coincided with a 32 protein (a helix-destabilizing protein) (Hurley et al.,
similar increase in the rate of mutation of base-substitu- 1993) and gene 45 protein, that are part of the replication
tion and frameshift mutations and a fourfold increase complex and have been shown to influence the accuracy
in the number of mutants containing multiple mutations of replication (Mufti, 1979, 1980; Topal and Sinha, 1983;
recovered to that of the parental vector. An increase in Watanabe and Goodman, 1978).
the number of multiple mutants along with the increase
The imbalance of deoxynucleotide triphosphate pools
in mutation rate indicates that the incidence and not the
has been suggested to influence the efficiency and accu-specificity of mutations occurring during the single round
racy of HIV-1 replication and the fidelity of purified HIV-of HIV-1 replication was influenced by mutation of the
1 reverse transcriptase (Bebenek et al., 1992; Martinezvpr gene.
et al., 1994; Meyerhans et al., 1994; Vartanian et al., 1994).The mechanism by which the vpr gene influences the
A possible effect of the vpr gene on HIV-1 reverse tran-mutation rate, as well as the function(s) of the vpr gene
scription could be to influence the access of deoxy-in the replication cycle of HIV-1, is not entirely clear; the
nucleotide triphosphates to reverse transcriptase.influence of vpr on the mutation rate that was observed
in this study could be either direct or indirect. However,
our findings indicate that the vpr gene influences an early
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